FDA Probes into GlaxoSmithKline's Zofran

The investigation is focused around active ingredient ondansetron. It is feared that the ingredient could cause QT interval prolongation, potentially leading to abnormal heart rhythms.

The US FDA has initiated an investigation into GlaxoSmithKline's Zofran medication, used to treat nausea, following concerns that the drug could distort the electrical activity of the heart.

The investigation is focused around active ingredient ondansetron. It is feared that the ingredient could cause QT interval prolongation, potentially leading to abnormal heart rhythms.

The investigation will also include generic versions of Zofran. The drug was once considered integral to GlaxoSmithKline's performance, but the drug has lost importance with the advent of generic competition.

The FDA has acted quickly to enforce